Abstract:<h3 class="article-section__sub-title section1"> Background</h3><p>Prostate cancer that recurs after initial treatment inevitably progresses to castration‐resistant prostate cancer (CRPC), the lethal stage of the disease. Despite improvements in outcomes from next generation androgen receptor (AR)‐axis inhibitors, CRPC remains incurable. Therapeutic strategies to target AR antagonist resistance are urgently needed to improve outcomes for men with this lethal form of prostate cancer.</p><h3 class="article-section__sub-title section1"> Methods</h3><p>Apoptosis and BCL2 family signaling were characterized in cell line models of CRPC. Quantitative real‐time polymerase chain reaction and Western blot analysis were used to determine BCL2 expression levels. Drug sensitivity was determined by proliferation, survival and apoptosis analysis. Protein‐protein interactions were evaluated by coimmunoprecipitation followed by Western blot detection.</p><h3 class="article-section__sub-title section1"> Results</h3><p>In the present study, we identify antiapoptotic BCL2 protein signaling as a mechanism of resistance to AR antagonist enzalutamide. In CRPC cell line models, we found that BCL‐xL and MCL‐1 proteins block apoptosis through binding and sequestering proapoptotic proteins BIM and BAX, resulting in cell survival in response to enzalutamide. Treatment with BH3‐mimetics targeting BCL‐xL or MCL‐1 disrupts these interactions and activates apoptosis, sensitizing CRPC cells to enzalutamide. Importantly, we demonstrate that PI3K/Akt signaling is activated in response to enzalutamide and mediates apoptosis evasion through inactivation of BAD, a BH3‐only protein that activates proapoptotic signlaing through inhbition of BCL‐xL. Inhibition of Akt activates BAD, resulting in increased apoptosis and sensitivity to enzalutamide, demonstrating an alternative therapeutic strategy to target drug resistance.</p><h3 class="article-section__sub-title section1"> Conclusions</h3><p>These results demonstrate that CRPC cells employ multiple mechanisms to mediate apoptosis evasion through BCL2 signaling, suggesting this pathway is critical for survival. This study provides a strong preclinical rationale for developing therapeutic strategies to target antiapoptotic BCL2 signaling in combination with AR antagonists to improve treatment options for patients with advanced prostate cancer.</p>

Effect of Androgen Blockade on Autophagy and Apoptosis in Bladder Cancer UM-UC-3 Cells

AMPK-mTOR-ULK1 axis activation-dependent autophagy promotes hydroxycamptothecin-induced apoptosis in human bladder cancer cells

Sodium Butyrate Inhibits Migration and Induces AMPK-mTOR Pathway-Dependent Autophagy and ROS-mediated Apoptosis Via the Mir-139-5p/bmi-1 Axis in Human Bladder Cancer Cells.

Inhibition of autophagy leads to increased apoptosis in LNCaP cells under androgen deprivation conditions

Targeted Inhibition of Mtor by BML-275 Induces Mitochondrial-Mediated Apoptosis and Autophagy in Prostate Cancer.

Promotion of Pirarubicin-Induced Apoptosis of Bladder Cancer Cells (BIU-87) Through Inhibiton of Autophagy by 3-Methyladenine

Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model

Autophagy flux in bladder cancer: Cell death crosstalk, drug and nanotherapeutics

Blockage of AMPK-ULK1 pathway mediated autophagy promotes cell apoptosis to increase doxorubicin sensitivity in breast cancer (BC) cells: an in vitro study

Thymoquinone Suppresses the Proliferation, Migration and Invasiveness through Regulating ROS, Autophagic Flux and miR-877-5p in Human Bladder Carcinoma Cells.

Simultaneous Autophagy and Androgen Receptor Inhibition in a Prostate Cancer Xenograft Model

Anaphylactic Hypersensitivity Induced in Rabbits to Foreign Proteins in Freund's Adjuvant.∗

Hypoxia-Induced Autophagy Enhances Cisplatin Resistance in Human Bladder Cancer Cells by Targeting Hypoxia-Inducible Factor-1α

[Dermoid cyst of the spermatic cord].

Inhibition Of Androgen Induces Autophagy In Benign Prostate Epithelial Cells

[Cisplatin Enhances Apoptosis in Bladder Cancer Cells Via Autophagy].

Ambra1 Induces Autophagy and Desensitizes Human Prostate Cancer Cells to Cisplatin.

Targeting prosurvival BCL2 signaling through Akt blockade sensitizes castration‐resistant prostate cancer cells to enzalutamide

Betulinic acid induces autophagy-dependent apoptosis via Bmi-1/ROS/AMPK-mTOR-ULK1 axis in human bladder cancer cells

The Effects Of Early Versus Delayed Castration Targeting Androgen On Prolonging Survival In A Mouse Model Of Bladder Cancer

Artesunate induces autophagy dependent apoptosis through upregulating ROS and activating AMPK-mTOR-ULK1 axis in human bladder cancer cells